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ABSTRACT
Objective: To explore the impact of providing
additional information about the potential benefits
of simvastatin in a patient leaflet on attitudes and
beliefs.
Design: Interview-based study using a generic
qualitative approach and framework analysis.
Participants: 21 participants receiving a prescription
for simvastatin were recruited from a general
practitioner practice (from a total of 120). 8
participants were women; the age range was 55–92.
Intervention: Participants were provided with leaflets
showing one of 3 types of additional benefit
information: (1) textual statement, (2) number
needed to treat (NNT) or (3) natural frequency.
Semistructured interviews explored patient’s attitudes
and beliefs.
Results: A descriptive narrative of preferences for
format suggested patients prefer textual as opposed to
numerical benefit information. Significant barriers to
the acceptance of numerical benefit information
included difficulty in understanding the numbers.
Patients overestimated the benefits of statins and
expressed surprise at the numerical information.
Conclusions: Textual information was preferred but
numerical information, in particular in the form of a
natural frequency, may help patients make judgements
about their medicines. NNTs were found to be very
difficult to understand. This raises the prospect that
some patients might reject medicines because of
disappointment with the perceived low benefits of their
medicines. The self-reported impact on behaviour
appeared minimal with reports of intentions to ‘do
what the doctor tells me’. Further research is needed to
explore the impact of such statements on people who
are yet to be prescribed a statin.
INTRODUCTION
For patients to take their medicines safely
and effectively, it is important that they
receive good quality information about their
treatments. Across the European Union, all
licensed medicines are required to be pro-
vided with written medicines information in
the form of a patient information leaﬂet
(PIL). Frequently, the PIL is the only written
information a patient will receive about their
medicines.1 PILs provide information about
medicines such as:
1. What X is and what it is used for
2. What you need to know before you take X
3. How to take X
4. Possible side effects
5. How to store X
6. Contents of the pack and other
information.
PILs are available on http://www.
medicines.org.uk.2 3 Information about side
effects (adverse effects) is presented in the
format of a qualitative descriptor for ﬁve
bands of risk alongside a natural frequency
(such as ‘common—affects less than 1 in 10
Strengths and limitations of this study
▪ This study recruited actual users of medicines in
order to explore their opinions on the inclusion
of benefit information about their own treat-
ments. Previous studies have generally used
hypothetical samples or hypothetical medicines
and situations.
▪ The participants recruited to this study were
broadly representative of the general practice
population who take simvastatin.
▪ We found that patients overestimated the benefits
of statins and expressed surprise at the numer-
ical information. Without information about the
benefits and harms of their medicines, patients
are not in a position to make informed choices
about them.
▪ This study did not measure directly the impact of
providing benefit information, it only explored
self-reported behaviours. The self-reported
impact on behaviour appeared minimal.
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people’) as recommended in an European Medicines
Agency Guideline.3 4
A common criticism of PILs is that they are too nega-
tive and can focus too heavily on side effect informa-
tion.5 In order to redress the balance, medicine
regulators have recently suggested that leaﬂets should
also include information about the beneﬁts of medi-
cines.6 There is no universally agreed deﬁnition of what
‘beneﬁt’ information encompasses, but it tends to
include information about how the medicine works and
its effectiveness.
Recently in the UK, the National Institute for Health
and Care Excellence (NICE) has published guidance
which recommends a wider use of statins, a class of
lipid-lowering medications used in the treatment of car-
diovascular disease.7 8 Critics of this change suggest that
the beneﬁts for low-risk patients often do not outweigh
the possible side effects of the medicine,9 10 as well as its
effect of ‘medicalising’ healthy people.
NICE recommends that doctors give clear information
to patients on the beneﬁts of their treatments,11 but this
can be challenging to do well. This is because there are
different statistical methods for communicating beneﬁts,
some of which can be more persuasive than others.12
Furthermore, it can be complex to communicate these
data to patients, as a number of patients struggle with the
numerical concepts used to communicate beneﬁts.13–15
The mandated PIL is the only regulated written infor-
mation that a patient receives with their medicines and
is included in every medicine pack. Therefore, such leaf-
lets might be part of the solution to providing better
quality information about the beneﬁts of medicines to
patients. However, currently little is known about prefer-
ence for format or the potential impact of providing
beneﬁt information in a PIL.
Some studies have shown that presenting beneﬁt
information has a positive effect on positive judgement
and the intention to take a medicine.16 17 Others have
found that patients are more inﬂuenced by information
on the adverse effects of medicines, rather than the ben-
eﬁts.18 Also, it has been shown that there can be signiﬁ-
cant concerns associated with the provision of beneﬁt
information to patients. A study from our research
group found that the provision of numerical beneﬁt
information provoked strong feelings of shock and
anxiety when the numerical beneﬁts of an antiplatelet
medicine were presented to a representative sample of
older people.
However, such research has not yet been undertaken
with people who are asked to read the beneﬁt informa-
tion about a medicine they are actually taking.
This study aimed to evaluate the following:
▸ The impact of providing beneﬁt information about
simvastatin in a PIL on the attitudes and beliefs that
the actual users of simvastatin hold about their
treatments.
▸ Patients’ preferences for the inclusion and type of
format of beneﬁt information in a PIL.
METHODS
Design
This is a qualitative study using semistructured,
face-to-face interviews conducted using a topic guide
(see online supplementary appendix 1). Interviews
lasted ∼1 hour and were conducted in the patient’s own
home by the researcher (RD—PhD candidate). A quali-
tative approach is the most appropriate method to
address the main objective, which is to explore the atti-
tudes and beliefs of patients who might receive this type
of information.
Participants and setting
Participants were recruited from a general practitioner
(GP) practice in Bradford, UK, via a database search
and were invited by letter to participate in audio-
recorded interviews.
A purposive sampling strategy was employed to recruit
patients already prescribed simvastatin for prior myocar-
dial infarction (MI) or established coronary heart
disease (CHD) (such as angina, unstable angina, previ-
ous coronary artery bypass graft (CABG) or angioplasty).
The sample was intended to have similar demographic
characteristics to sample recruited to the Heart
Protection Study (HPS),19 as this study was used to gen-
erate the data for the beneﬁt statements. Participants
were excluded if they were care home residents, receiv-
ing palliative care, had a cognitive impairment or were
non-English speaking.
Materials
During the interviews, patients were shown three PILs
produced for the purpose of the study but based on
PILs commonly provided with simvastatin. Participants
had as much time as they needed to review the PILs.
Simvastatin was chosen for the following reasons:
▸ It is a commonly prescribed medicine—providing a
large sampling frame from which to recruit.
▸ Simvastatin itself does not alleviate symptoms.
Consequently, information provided about the
chance of beneﬁt may have particular signiﬁcance for
patients.
▸ Our previous research has shown that medicines per-
ceived as having quite a small chance of beneﬁt can
create upset among participants.5 We wished to
explore different magnitudes of beneﬁt.
▸ Although the individual beneﬁts may still be per-
ceived as small, the population beneﬁts of statin pre-
scribing are potentially considerable. Understanding
how patients perceive individual beneﬁts might have
an impact on willingness to take a treatment and con-
sequently on population beneﬁts.
Data were taken from the HPS, the largest published
trial of simvastatin and which was funded by the UK
Medical Research Council and the British Heart
Foundation charity.19 We had identiﬁed a number of
potential sources of data, including NICE guidelines—
national evidence-based clinical guidelines in the UK.
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NICE guidelines on statins for the prevention of cardio-
vascular events20 are based on a meta-analysis of studies
into a variety of statins. Hence this could not be used,
as the data needed to be speciﬁc to simvastatin. We
identiﬁed four studies speciﬁc to simvastatin in NICE
guidelines and chose the HPS because it provides effect-
iveness data for a secondary prevention or high-risk
population. With the aim that the statements were as
relevant to the individual as possible (without the need
for a risk calculator which is not feasible in a PIL). The
primary end points for which beneﬁt data were pre-
sented were the likelihood of having a heart attack or
stroke (and the standard equation for calculating
number needed to treat (NNT) was used).
The leaﬂets were designed to look like PILs typically
available in the UK. Simvastatin was given the hypothet-
ical name ‘Rebastatin’ and each leaﬂet was marked with
a highlighted section that stated ‘This leaﬂet is for
research purposes only’. The hypothetical name and
highlighting were to ensure the leaﬂet was not mistaken
for an actual PIL.
Three leaﬂets containing the following beneﬁt state-
ments were presented to the participants.
Textual: Rebastatin can reduce the chance of you having
a heart attack or stroke. It does this by lowering levels of
cholesterol and triglycerides in your blood.
Numerical: number needed to treat: If 17 people take
Rebastatin over the next 5 years, one of them will be pre-
vented from having a heart attack or stroke.
Numerical: natural frequency: In 100 people like you who
do not take this medicine, 28 will have a heart attack or
stroke. But if they all take Rebastatin over the next
5 years, 22 will have a heart attack or stroke.
DATA ANALYSIS
Data were organised and analysed by Framework ana-
lysis, using the following processes.
Familiarisation
After the interviews, ﬁeld notes were made and initial
categories for coding considered. Emerging themes
were considered and discussed with the research team.
Identifying a thematic framework
One transcript was used to chart emerging codes which
were developed into initial coding categories. These
coding categories were checked against samples of the
transcripts by three members of the research team (RD,
JM and PK). The thematic framework was applied to
each interview (see online supplementary appendix 2).
Indexing
The thematic framework was then applied to each inter-
view and relevant data coded according to the frame-
work. A software package, NVIVO, was used to manage
the data (QSR International Pty, NVivo qualitative data
analysis software. Version 9, 2010).
Charting
The indexed data were then sorted into charts. Each
chart presented a main theme; every patient was repre-
sented by a row and each column was designated a sub-
theme. This allowed for all pertinent quotes from
patients on a particular subtheme to be charted in a
visually accessible way so that the researcher could view a
summary of the data, yet view the different themes emer-
ging by case and/or category.
Mapping and interpretation
The ﬁnal stage saw a process of mapping and interpret-
ation which was undertaken by RD and JM during two
full-day meetings. RD and JM undertook a ‘post-it note’
exercise where each category and subcategory in the
charts were summarised and arranged in emerging
themes. Each researcher took a category and organise
the emerging themes into subthemes until a coherent
set of subthemes had been developed for each category.
Field notes and mind maps were developed to present
the emergent themes and the most-important themes
identiﬁed from the framework.
Research ethics consideration
Research ethics approval was obtained from NRES
Committee Yorkshire and the Humber—Humber
Bridge: 13/YH/0180.
All participants received a PIL with details of the
research prior to providing written informed consent
prior to participation.
RESULTS
Letters were sent to 120 patients, of whom, 21
responded positively (17.5% positive response rate) and
were interviewed: 20 in their own homes and 1 at their
GP practice.
Eight of the participants were women. The age range
was 55–92 (median age 75). Thirteen participants were
educated to school level, three were educated to age 18
and ﬁve had completed higher education. Participants
were currently receiving multiple prescribed medicines
(range 4–10, median=7).
A range of views were obtained. The data were
charted and organised into four broad themes which
present a descriptive narrative of the range of attitudes
and beliefs expressed regarding the beneﬁt information.
1. Preferences for each format of beneﬁt information.
2. Barriers to the inclusion of beneﬁt information in
PILs.
3. The impact on users of simvastatin of providing
beneﬁt information.
4. Desirable attributes for future beneﬁt information.
Preferences for each format of benefit information
Textual
The dominant perspective was that the textual format
was preferable. The textual format was viewed as
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‘positive’, ‘easy to read’ and ‘helpful’ as it provided add-
itional rationale for taking the medicine. It was per-
ceived as reassuring and met participants’ preferences
for information that reinforced their decision to take
the medicine.
The most positive one to read is obviously [textual state-
ment] because it’s just telling you that it’s gonna reduce
your chance and you think that’s good. I stand a good
chance of not having a heart attack or stroke. (P01, M, 75)
A less common perspective was that the textual format
was perceived as insufﬁcient and sometimes considered
to be too cautious. It was reported that participants felt
they could not develop a deeper understanding about
the proportion of participants who would beneﬁt from
the treatment, especially when they compared the
textual statement to one of the numerical statements:
I like to see that upfront [textual statement] but I’d
perhaps be looking for perhaps something more…quan-
tiﬁed beneﬁts to back that up. I have… having, you know,
talked about it, I think one of the quantiﬁed statements
would be helpful. (P09, M, 72)
Number needed to treat
This format appeared to cause a great deal of confusion.
A common occurrence was for participants to misinter-
pret that 1 extra person would be saved but the other 16
would have a heart attack.
It’s a bit like saying a lottery, we’ve got seventeen people,
one might be lucky and sixteen won’t be lucky…The ball
will roll and it could be that you could be the lucky one
or not…your chances are one in seventeen, it almost says
it’s luck…it sounds like sixteen people are not gonna
survive but one will. (P19, M, 76)
The provision of the NNT also had the potential to
create an emotional response. It appeared to undermine
participant’s conﬁdence in their medicines, created
anxiety and removed hope:
The one in seventeen, I don’t think would give me a lot
of conﬁdence. (P11, M, 77)
Less commonly, the participants responded positively
about the NNT perceiving the statement as easy to read:
It’s just clearer…you don’t have to think about it. (P20, F, 55)
This was in comparison to the natural frequency,
which often took some time to be understood.
Natural frequency
Although concerns were expressed about the natural fre-
quency statements, it was viewed as helpful for those
who could invest time and effort into understanding it.
However, consistently participants continued to struggle
to understand the natural frequency, and a group of par-
ticipants did not understand it at all.
The natural frequency format tended to be regarded
as positive in comparison to the NNT, as the numbers
were perceived as more favourable. However, when con-
sidered alone it did not appear to convey large beneﬁts
to the patient and this was frequently viewed as
disappointing:
It’s not terribly impressive is it? A reduction from 28 to
22? But I suppose as a percentage it’s about, mm, it’s not
a bad percentage, about 25 percent about 25…yeah, 28
down to 22…well, will that worry people being told those
ﬁgures? I think a lot of people might be worried. They
might think “oh, I’m the unlucky 1 in 5”, we’ll call 22
one in 5. (P17, M, 81)
The level of beneﬁt perceived from the natural fre-
quency created a negative perception of the statement.
However, it was the stated beneﬁts of the medicine that
were found disappointing, rather than the numerical
format. Indeed, it was difﬁcult for participants to separ-
ate their disappointment with the data from that asso-
ciated with the format of the statement.
Not a very big decrease is it in people? 28 from 22. It’s
like saying 28% of you will have a heart attack if you take
this tablet 22 of you will, so only 6% won’t…I honestly
don’t think it’s a large enough percentage of people, six.
I think it should tell you a lot more will [beneﬁt]… I
think it’s a bit on the low side. (P11, M, 77)
One perspective presented was that the natural fre-
quency statement was viewed as sounding threatening;
this undermined conﬁdence in medicines:
I think that’s a bit frightening because you’ll be looking
out and thinking am I going to be one of those 28 or 22
all the time I think. (P14, F, 66)
Barriers to the inclusion of benefit information in PILs
During the course of the interviews, the participants
who said they would not typically read their leaﬂets
engaged with and valued the beneﬁt information, but
still stated that they would be unlikely to read the leaﬂet
in a natural situation.
I don’t really think [I would read the leaﬂet] to be
honest because at the moment I’m taking it because I’ve
been told I need it. (P16, M, 68)
For those who stated they did not or would not read
the leaﬂet (and therefore the beneﬁt information), the
stated reason was a lack of perceived relevance to their
individual situation. The numerical information was
viewed as irrelevant because those participants wanted
to know the odds of what would happen to them indi-
vidually and not the wider population.
It was also seen as potentially irrelevant; it was pointed
out by participants that by the time patients receive the
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leaﬂet they have already made a decision to obtain the
medicine. Therefore, timing of provision is an issue:
You wouldn’t see this leaﬂet unless you were taking the
medicine would you? (P05, M, 75)
Denial of the potential consequences of their own
health condition was expressed. A recurrent view was
that participants do not appear to want to hear the statis-
tical facts about their medicine, as this was viewed as
unpalatable.
I don’t want to know that, I want them to tell me
Simvastatin is doing you good and it will help prevent
heart attacks, I don’t want to know that X number are
still gonna have a heart attack. (P01, M, 75)
A major barrier to accessing the beneﬁt information
was the challenge in understanding the beneﬁt informa-
tion. There were occurrences where participants made
no attempt to try and understand it. However, a signiﬁ-
cant proportion was able to understand the provided
numerical beneﬁt information.
The impact of providing benefit information for users of
simvastatin
Satisfaction
The participants reported that numerical beneﬁt data
had the potential to have a negative impact, provoking
anxiety, worry and doubt; it was apparent that the infor-
mation has the potential to be perceived as upsetting.
The cause of this upset was the poor odds associated
with the treatment:
It doesn’t seem as if it helps a lot of people that, not in
that length of time. There are only six people… Does
that sound like sense? (P21, F, 84)
The textual beneﬁt information was viewed as helpful
and useful to know. Numerical information provided
better clarity about treatments, more information about
how the medicine was going to beneﬁt them and how it
would do this
I think you do need some facts and ﬁgures, it’s interest-
ing to know that if I take them, people who take statins
are less likely and the percentage is worth knowing. (P05,
M, 75)
A more exceptional perspective was that the informa-
tion gave participant’s conﬁdence about their medicines
and was encouraging and optimistic. The main beneﬁt
stated was that it met some participants’ expectations of
healthcare professionals having a duty to inform about
the beneﬁts of treatments. It satisﬁed their sense of
‘needing to know’:
Not everybody will want quantiﬁed information or quan-
tiﬁed beneﬁts, but I think equally there’ll be a propor-
tion who will look at the leaﬂet and will be looking for
quantiﬁed information so they can actually say in quanti-
ﬁed terms what the beneﬁts are likely to be, so I would
say yes. (P09, M, 72)
Knowledge and understanding
For many, the provision of beneﬁt information in a PIL
had no apparent impact on their knowledge or under-
standing about their medicines. There were several
reasons for this. The information, particularly the
numerical information, was viewed as too complicated.
Others did not read the leaﬂet at all.
There were examples of participants who developed a
deeper insight into the beneﬁts of their medicine when
reading the beneﬁt statements for the purpose of the
research study:
Honestly it has [helped me understand]…. It’s brought it
home to me a bit… I’ll take them with more joy
[laughs]. (P16, M, 68)
For one participant in particular it put the concerns
she had about her condition and treatment into
context, which surprised her, but was very positive:
My father died at 44 and his brother died at 40…so I’ve
always thought the percentage was a lot higher from my
own personal experience, I thought when I was diag-
nosed that was it, I wasn’t going to make it… But that’s
more reassuring to me because, alright 22 will have a
heart attack or stroke but 78 won’t if you are good and
take the medicine. (P08, F, 56)
When the information did have an impact, this was
sometimes a mix of a positive and negative effect. A
minority view was that the provision of this type of
numerical information helped with the development of
a deeper understanding about the beneﬁts of their treat-
ments and encouraged participants to weigh up the
advantages and disadvantages of treatments in more
detail, but it also created more emotional responses and
was often perceived as negative by the reader.
Despite the negative emotional responses, there was a
sense of satisfaction that the numerical beneﬁt informa-
tion was included too. Participants wanted knowledge
about the medicines to be made available.
I know it does make some people anxious…but I still
think it’s a good idea to put it in. (P06, M, 88)
Decision-making and medicine-taking
Concerns about the beneﬁt information occasionally
undermined the conﬁdence that participants had in
their medicines, leading to apprehensions that its inclu-
sion in written medicines information might result in
people being ‘put off’ from taking their medicines.
For this group of participants, the beneﬁt information
was in direct conﬂict with their positive beliefs about
their medicines and desire for information reinforcing
medicine taking. The numerical beneﬁt information
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provided in the leaﬂets did not support patients with
this, causing some anxiety and unease:
It doesn’t really give me a great deal of conﬁdence that
I’m going to be the one who’s going to be prevented
from having the heart attack or stroke. (P09, M, 72)
In this sample, it did not appear that presenting such
beneﬁt information at this stage would have a signiﬁcant
inﬂuence on actual decision-making and medicine-
taking for the participants. The biggest reported inﬂu-
ence in this respect was the recommendation of their
GP:
If the doctor told me to stick me head in a gas oven, I
would do. I tend to believe in ‘em. I’ve had good results
and I mostly go along with ‘em… (P06, M, 88)
A prevailing view was that as the decision about
whether to take simvastatin or not had been made previ-
ously, sometimes decades before, the numerical beneﬁt
information was not necessarily viewed as something
that could impact on decision-making. Instead, the
numerical beneﬁt information was something that was
desired in order to reinforce the decision to take the
medicine.
I’m not as impressed with that [numerical format], that’s
not as reassuring … it’s just numbers and it’s not as per-
sonal. Reading [textual statement] it’s speaking to me per-
sonally and it’s giving me a bit of reassurance. (P20, F, 55)
One dominant perspective was that the participants
would carry on taking simvastatin and hope that they
would be one of those to beneﬁt. The beneﬁt informa-
tion did not appear to have a negative impact on their
approach to a medicine they were already taking.
Desirable attributes of benefit information
The beneﬁt information did not appear to affect the
balance of the leaﬂet—one of the reasons for its inclu-
sion. One perspective presented was that it only served
to make the leaﬂet appear more negative. Another view
was that the side-effect information was perceived as so
negative, the provision of beneﬁt information could
never balance that. The beneﬁt information that was
provided about simvastatin did not have sufﬁcient posi-
tive impact to appear attractive:
I think the problem with these sorts of things is that
there is too much emphasis on the bad side-effects. I
know we’ve got to know, I know there is a duty of care to
tell us all the bad things that might happen but I want to
be drawn into what is good… I want the beneﬁts to
scream out at me. (P20, F, 55)
The appeal of qualifying words such as ‘drop’ to
emphasise reduction in risk or ‘increase’ to emphasise
improvements provided by the treatment was noted.
Participants wanted the information to be positive and
to stress the beneﬁts of the medicine.
I would like it to be more positive, take Rebastatin and
you will beneﬁt in the following terms…your likelihood
of having a heart attack will drop from twenty-eight in a
hundred to twenty-two in a hundred, I’d rather any infor-
mation was presented in a positive way. (P09, M, TN)
There was a view that this could be achieved by using
a combined textual and numerical statement. Having
this textual statement as a precursor to a numerical state-
ment appeared to reduce the disappointment and
reinforce the beneﬁts of the medicines that participants
desire to hear more about:
If you’re going to say it reduces the chances then tell
people exactly how many it will reduce it by. (P08, F, 56)
This would mimic to a degree the way that side effect
information is currently expressed in PILs (with textual
and numerical information).
DISCUSSION
The provision of information about the potential bene-
ﬁts of a statin in a patient leaﬂet provoked complex and
often emotive responses in people taking the medicine.
This study demonstrates the range of opinions on, and
the preferences for, format for beneﬁt information. The
dominant view was that textual information was prefer-
able. In particular, there was a desire for additional
information about the rationale for treatment.
It was also apparent that a small subset of patients
developed a deeper insight about their medicines after
reading the numerical statements. Natural frequencies
appeared to be better suited to giving participants an
understanding of the likelihood of beneﬁt, which is a
ﬁnding supported by previous studies.21–23 However, the
natural frequency format was still too difﬁcult for many
participants to engage with.
Although the NNT was described as short and easy to
read, it was frequently misinterpreted. This misinterpret-
ation generated a considerable emotional response. The
ﬁndings suggest that NNTs are not easily understood by
lay people who frequently misinterpret the beneﬁts of
their treatment mean that 1 in 17 (in this case) will be
saved, while the remainder come to harm. This is a
ﬁnding that has been noted in other studies.24–27
The participants frequently overestimated the beneﬁts
of their medicine and when presented with numerical
information about simvastatin this provoked surprise
and disappointment. This response had been noted in a
similar study with medicine takers who were also shown
such numerical information but, importantly, not for a
medicine they were actually taking. In that study,
patients expressed shock and nihilism in response to
reading beneﬁt statements.5 It was concerning in that
study that the routine provision of such information
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might promote decision-making based on the affect
heuristic, rather than a rational consideration of the
information.
This extreme emotional response was less noteworthy
in this study of actual users of medicines. It was apparent
that the participants were often shocked or disappointed
with the beneﬁt information and with the uncertainty
associated with the effectiveness of the treatment.
Previous experience with taking the medicine facilitated
the appraisal of illness and treatment in the context of
participants’ current health state and appeared to play
some role in mitigating this unease.28 29
This suggests that the users of medicines may not
reject their treatments despite their concerns about per-
ceived low beneﬁts and will weigh up the likelihood of
beneﬁt and risk of harm of their treatments before alter-
ing their behaviour. This is not to say that the informa-
tion should not be given; the concepts of patient
empowerment and engagement are based on transpar-
ent provision of all relevant information. If the outcome
of a reasoned assessment of the information is that a
medicine is not right for an individual, then that deci-
sion must be respected.
Participants also desired information which reassured
them and encouraged them to take their medicines.
The numerical data on simvastatin failed to achieve this
and was perceived as disappointing. However, it was
apparent that the study participants still desire informa-
tion about the potential beneﬁts of their medicines, that
is factual information which (may) reassure them and
respond to their desire to continue to take their medi-
cines as prescribed.
In the current study, the inﬂuence of the GP was also
a strong moderating factor. Patients reported faith and
trust in their GPs and the dominant perspective was that
participants would do what their doctor tells them.
Further research is needed to explore the inﬂuence of
the GP. Concerns about patients rejecting medicines
because of an emotional, rather than reasoned, response
to the beneﬁt information did not appear to be
founded. Furthermore, the beneﬁt information did not
undermine the conﬁdence that people had in their
doctor’s advice in such a way that it might lead to a
change in medicine-taking.
It is possible that, as these patients were in receipt of
long-term prescriptions for simvastatin, they might be
inﬂuenced by the status quo bias which is the ‘tendency
to maintain a previous decision either by actively taking
the default or by doing nothing’.30 31 It is possible that
beneﬁt information might impact differently on those
who are considering a new treatment, that is, for patients
who have not yet made a decision about taking it.
We know that over 70% of people read at least some
of the PIL when they are ﬁrst prescribed a medicine,32
but that leaves a signiﬁcant proportion, as reﬂected in
the current ﬁndings, for whom the inclusion of beneﬁt
information could not have an impact, as they do not
read the leaﬂet. This is a signiﬁcant barrier in engaging
people about the beneﬁts of their treatments by using
written PILs, although other sources of information are
available to people, notably online.
Strengths and limitations of the research
This study recruited actual users of medicines in order
to explore their opinions on the inclusion of beneﬁt
information about their own treatments. Previous studies
have generally used hypothetical samples or hypothetical
medicines and situations.16 33–36
The participants recruited to this study were broadly
representative of the general practice population who take
simvastatin. However, the sample is small and this group
who volunteered to take part in research might hold dif-
ferent views to those who declined; consequently, there
may be a degree of selection bias within the sample.
This study did not measure directly the impact of pro-
viding beneﬁt information, it only explored self-reported
behaviours. It is possible that while the participants
might have reported that they would ‘do what the
doctor tells them’ and remain adherent to their medi-
cines, the provision of beneﬁt information might in
practice change medicine-taking behaviour. More
research examining this possibility is needed.
Another limitation of the study is the choice of data
on the beneﬁts of statins to a targeted sample. This
study used the ﬁndings from the HPS study, however, it
is acknowledged that other data may alter the magni-
tude of beneﬁt. The producers of beneﬁt information
for patients need to ensure a transparent process for
choosing and presenting beneﬁt data.
CONCLUSIONS
In 2014, NICE published guidance recommending a
wider use of statins in the UK, reducing the prognostic
threshold for initiating treatment,20 which will impact par-
ticularly on their use in primary prevention of heart and
vascular disease. Opponents suggest that the beneﬁts for
low-risk patients often do not outweigh the possible side
effects of the drug and that the risk–beneﬁt information
for statins is inadequately communicated.37 38
There are shortcomings with the availability and inter-
pretation of data on the beneﬁts and harms of statins
and so uncertainty about their effectiveness. This will
impact on the ability of healthcare professionals to
effectively communicate risks and harms to patients and
can be a barrier to informed decision-making. However,
this study suggests that currently in the absence of the
provision of numerical information about beneﬁts many
patients overestimate the beneﬁts of their statins.
Without information about the beneﬁts and harms of
their medicines, patients are not in a position to make
informed choices about them.
While there are barriers to the use of a PIL, it is a man-
datory and regulated piece of information that should be
provided to every patient who is prescribed a licensed
medicine. The PIL seems a logical place for the inclusion
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of information about the potential beneﬁts of medicines
—after all that is where the numerical information about
side effects and their likelihood is to be found. The main
disadvantages are timing (the PIL is provided when the
medicine is dispensed and not during consultation) and
visibility (only two-thirds of patients read a PIL when the
medicine is ﬁrst prescribed; the proportion is much
lower for subsequent prescriptions).
The ﬁndings of this study suggest that people value the
addition of extra textual information about the rationale
of treatments. The provision of numerical information is
more problematic as many people do not understand or
value this information. However, there is a perspective that
if the providers of medicines information know the numer-
ical beneﬁts of medicines, then this should be provided in
the leaﬂet; not to do so would be to withhold information
from patients. There was an expectation from participants
that extra textual information about the rationale for a
treatment would be enhanced by the provision of numer-
ical information about its likely effectiveness.
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